这是描述信息
搜索
这是描述信息
这是描述信息
All categories
All categories

product

Number of views:
1001

Fleroxacin glucose injection

Product description
Date of approval: November 14, 2006 Pilosin
 
Date of revision: December 02, 2011
 
          July 05, 2017
 
Fluroxacin glucose injection instructions
 
Please read the instructions carefully and use them under the guidance of a physician.
 
For food and feed processing
 
caveat:
 
Serious adverse reactions, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and increased myasthenia gravis.
 
· The use of fluoroquinolone drugs (including fleroxacin glucose injection) has been reported to have both severe and potentially irreversible serious adverse effects (see [Precautions]), including:
 
o Tendinitis and tendon rupture (see [Precautions])
 
o Peripheral neuropathy (see [Precautions])
 
o The effects of the central nervous system (see [Notes])
 
When these serious adverse reactions occur (see [Precautions]), fleroxacin glucose injection should be stopped immediately and fluoroquinolone drugs should be avoided.
 
· Fluoroquinolone drugs may aggravate the symptoms of myasthenia gravis in patients with myasthenia gravis. Patients with a history of myasthenia gravis should be advised to avoid fleroxacin glucose injection (see [Precautions]).
 
· Serious adverse reactions have been reported due to the use of fluoroquinolone drugs (including fleroxacin glucose injection) (see [Precautions]). For patients belonging to the following indications, fleroxacin should be used without other medications. Glucose Injection:
 
o Acute exacerbation of chronic bronchitis (see [Indications] and [Usage and Dosage])
 
 
 
【Drug Name】
 
    Generic name: fleroxacin glucose injection
 
    English name: Fleroxacin and Glucose Injection
 
    Pinyin: Fuluoshaxing Putaotang Zhusheye
 
[Ingredients] The main component of this product is: fleroxacin, its chemical name is: 6,8-difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1- Piperazinyl)-4-oxo-3-quinolinecarboxylic acid.
 
    Chemical Structure:
 
 
 
 
 
 
 
 
 
    Molecular formula: C17H18F3N3O3
 
Molecular weight: 369.34
 
Excipients are: glucose, lactic acid.
 
【Properties】 This product is a clear liquid with no color, light yellow or yellowish green.
 
[indications]
 
It can be used for acute bronchitis caused by sensitive bacteria, chronic bronchitis and pneumonia and other respiratory infections; cystitis, pyelonephritis, prostatitis, epididymitis, Neisseria gonorrhoeae urinary tract infections; Digestive system infections such as Salmonella typhimurium infection, bacterial dysentery; skin soft tissue infection, bone infection, abdominal infection and pelvic infection.
 
Serious adverse reactions have been reported due to the use of fluoroquinolones (including fleroxacin glucose injection), and for some patients, acute exacerbations of chronic bronchitis are self-limiting, and fleroxacin glucose should be used without other medications. Injection.
 
[Specification] 100ml: fleroxacin 0.4g and glucose 5.0g
 
[Usage and Dosage] Slow intravenous infusion, 0.2 ~ 0.4g (based on fleroxacin), once a day.
 
【Adverse reactions】
 
1. Serious and other important adverse reactions
 
Disabling and potentially irreversible serious adverse effects, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects
 
l tendonitis and tendon rupture
 
l myasthenia gravis aggravation
 
l QT interval extension
 
l allergic reactions
 
l other serious and potentially fatal reactions
 
l The influence of the central nervous system
 
l peripheral neuropathy
 
l Clostridium difficile-associated diarrhea
 
l Interference with blood sugar
 
l Light sensitivity / phototoxicity
 
The above adverse reactions are described in detail under [Precautions].
 
Cardiovascular system: prolonged QT interval, torsade de pointive ventricular tachycardia, ventricular arrhythmia
 
Central nervous system: convulsions, toxic psychosis, tremors, agitation, anxiety, dizziness, confusion, hallucinations, delusions, depression, nightmares, insomnia, seizures, and very few situations can lead to suicidal thoughts or actions
 
Peripheral neuropathy: feeling disorganized, feeling dull, feeling of touch, pain, burning, tingling, numbness, weakness, or light touch, pain, temperature, position and vibration abnormalities, polyneuritis
 
Skeletal muscle system: joint pain, myalgia, muscle weakness, tension hypertonic tendonitis, tendon rupture, worsening myasthenia gravis
 
Hypersensitivity reactions: urticaria, itching and other serious skin reactions (such as toxic epidermal necrolysis, erythema multiforme), dyspnea, angioedema (including tongue, throat, pharynx or facial edema/swelling), Cardiovascular collapse, hypotension, loss of consciousness, airway obstruction (including bronchospasm, shortness of breath and acute respiratory distress), hypersensitivity pneumonitis, anaphylactic shock
 
Hepatobiliary system: hepatitis, jaundice, acute hepatic necrosis or liver failure
 
Urinary system: acute renal insufficiency or renal failure
 
Blood system: anemia, including hemolytic anemia and aplastic anemia, thrombocytopenia, including thrombotic thrombocytopenic purpura, leukopenia, neutropenia, pancytopenia, and/or other blood diseases
 
Others: fever, vasculitis, serum disease, Clostridium difficile-associated diarrhea, blood glucose disorder, photosensitivity/phototoxicity
 
2, gastrointestinal reactions are more common, can be manifested as abdominal discomfort or pain, diarrhea, nausea and vomiting, loss of appetite, jaundice and so on.
 
3, the central nervous system reaction may have dizziness, headache, excitement, lethargy or insomnia, direction disorders and so on.
 
4, allergic reactions have rash, itchy skin, urticaria, palpitations, convulsions, occasional exudative erythema multiforme and vascular nerves
 
Sexual edema, severe cases can occur in shock. A small number of patients have photosensitivity reactions.
 
5, a small number of patients can occur blood aminotransferase, serum creatinine, blood urea nitrogen increased, peripheral blood like white blood cells decreased, thrombocytopenia,
 
Mostly mild and transient.
 
6, can happen:
 
(1) seizures, mental disorders, irritability, confusion, hallucinations, tremors.
 
(2) Interstitial nephritis manifestations such as hematuria, fever, and rash.
 
(3) Crystalline urine, more common in high-dose applications.
 
(4) joint pain.
 
(5) phlebitis.
 
(6) Interstitial pneumonia: fever, cough, difficulty breathing, chest X-ray abnormalities and other performance.
 
(7) Achilles tendon inflammation, Achilles tendon rupture, muscle pain, fatigue, increased CPK, etc.
 
[Contraindications] 1. Those who are allergic to this product or quinolones are prohibited.
 
2. Pregnant women, lactating women and patients under 18 years of age are banned.
 
【Precautions】
 
1. Disabling and potentially irreversible serious adverse reactions, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects
 
The use of fluoroquinolone drugs has been reported to cause disabling and potentially irreversible serious adverse reactions in different organ systems of the same patient, usually including: tendonitis, tendon rupture, joint pain, myalgia, peripheral neuropathy and Central nervous system reactions (illusions, anxiety, depression, insomnia, severe headaches and confusion). These adverse effects can occur from hours to weeks after the use of fleroxacin glucose injection. These adverse events have been reported in patients of any age without prior risk factors.
 
2, tendonitis and tendon rupture
 
Fluoroquinolone drugs increase the risk of tendonitis and tendon rupture in patients of all ages. This adverse reaction most often occurs in the Achilles tendon, which may require surgical repair. There have also been reports of tendonitis and tendon rupture in the shoulders, hands, biceps, thumb and other tendon points. Tendinitis and tendon rupture can occur hours or days after the start of the use of fleroxacin glucose injection, or several months after the end of treatment. Tendinitis and tendon rupture can occur bilaterally. This risk is further increased in elderly patients over 60 years of age, patients taking corticosteroids, and patients undergoing kidney, heart or lung transplants. In addition to age and the use of corticosteroids, factors that independently increase the risk of tendon rupture include severe physical activity, renal failure, and previous tendon diseases such as rheumatoid arthritis. Tendinitis and tendon rupture also occur in patients who use fluoroquinolone drugs without the above risk factors. Tendon rupture can occur during or after treatment; it is also reported that tendon rupture occurs several months after the end of treatment. This product should be discontinued after the patient has muscle pain, swelling, inflammation or breakage. After signs of tendonitis or tendon rupture, patients should be advised to rest and contact a physician for a non-quinolone. Patients with a history of tendon disease or who have had tendinitis and tendon rupture should avoid fluoroquinolone drugs.
 
3, myasthenia gravis aggravation
 
Fluoroquinolone drugs, which have neuromuscular blocking activity, may aggravate the symptoms of myasthenia gravis in patients with myasthenia gravis. Serious adverse events after marketing, including death and need for ventilatory support, and patients with myasthenia gravis are associated with the use of fluoroquinolones. Patients with myasthenia gravis should avoid the use of fleroxacin glucose injection.
 
4, QT interval extension
 
Some fluoroquinolone drugs can prolong the QT interval of the electrocardiogram, and a few patients can have arrhythmia. Patients with spontaneously reported fluoroquinolone therapy during the post-marketing surveillance period have a rare torsade ventricular tachycardia. Patients with known QT prolongation, uncorrected hypokalemia patients, and patients with antiarrhythmic drugs of class IA (quinidine, procainamide) and class III (amiodarone, sotalol) The use of fleroxacin glucose injection should be avoided. Elderly patients are more susceptible to drug-related QT intervals.
 
5, allergic reactions
 
Serious allergic reactions have been reported using fluoroquinolone drugs. Some patients occur after the first dose, and some reactions can be accompanied by cardiovascular failure, loss of consciousness, tingling, swallowing or facial edema, difficulty breathing, urticaria, itching, and the like. Severe allergic reactions require emergency treatment with adrenaline. Fleroxacin glucose injection should be discontinued the first time there is a rash or any other signs of allergies. If necessary, oxygen can be delivered, intravenous steroids, airway treatment, including intubation and other measures.
 
6. Other serious and potentially fatal reactions
 
Other serious and potentially fatal incidents have been reported using fluoroquinolone drugs. Some of these events are due to allergies and some are unknown. These events can be severe and usually occur after multiple doses. Clinical manifestations may include one or more of the following symptoms: fever, rash, severe skin reaction (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome); vasculitis; joint pain; myalgia; Allergic pneumonia; interstitial nephritis; acute renal insufficiency or renal failure; hepatitis, jaundice, acute hepatic necrosis or liver failure; anemia, including hemolytic anemia and aplastic anemia; thrombocytopenia, including thrombotic thrombocytopenia Purpura; leukopenia; agranulocytosis; pancytopenia and/or other hematological abnormalities. The drug should be discontinued and measures taken immediately on the first occurrence of a rash, jaundice or any other allergic manifestation.
 
7, the impact of the central nervous system
 
The use of fluoroquinolone drugs, including fleroxacin glucose injection, has been reported to increase the risk of increased central nervous system adverse events, including convulsions and increased intracranial pressure (including pseudo-brain tumors) and psychosis caused by poisoning. The use of fluoroquinolone drugs may cause central nervous system reactions including anxiety, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and suicidal thoughts or behaviors. These reactions may occur after the first dose. If these reactions occur when the patient is taking fleroxacin glucose injection, stop the administration and take appropriate measures. As with all fluoroquinolone drugs, patients with known or suspected central nervous system disorders (such as severe cerebral arteriosclerosis, epilepsy) or patients with other risk factors (if there is a tendency to attack or a lower threshold for seizures) should be obtained. Fluroxacin glucose injection is used when the risk exceeds the risk.
 
8, peripheral neuropathy
 
Patients have been reported to use fluoroquinolone drugs to produce a rare sensory or sensorimotor axonal neuropathy that affects small and/or large axons, causing skin paresthesia, sensation of dullness, sensation of touch and weakness. For some patients, symptoms may occur soon after administration of fleroxacin glucose injection and may be irreversible. If the patient has symptoms of peripheral neuropathy, including pain, burning sensation, tingling, numbness and/or weakness, or other sensations, including changes in light touch, pain, temperature, position, and vibration, stop the drug immediately. Patients with a history of peripheral neuropathy should avoid the use of fluoroquinolone antibiotics.
 
9. Clostridium difficile-associated diarrhea
 
Almost all antibacterial drugs have been reported for C. difficile-associated diarrhea (CDAD), including fleroxacin glucose injection, ranging from mild diarrhea to severe colitis. Antimicrobial treatment changes the normal flora of the colon, resulting in overgrowth of C. difficile.
 
Toxins A and B produced by C. difficile are responsible for Clostridium difficile-associated diarrhea. The morbidity and mortality caused by highly toxic Clostridium are elevated, and these infections are ineffective and may require colectomy. After receiving antibiotics, the possibility of CDAD should be considered in the presence of diarrhea. Because CDAD may occur two months after treatment with antibacterial drugs, careful medical history is necessary.
 
If you suspect or confirm C. difficile-associated diarrhea, you may need to stop the antibiotics currently used against C. difficile. Appropriate supplementation of fluids and electrolytes, protein supplementation, antibiotic treatment for C. difficile should be performed, and surgical evaluation should be performed when clinical indications appear.
 
10, interference with blood sugar
 
There have been reports of fluoroquinolone antibiotics causing blood glucose disorders (such as symptomatic hyperglycemia and hypoglycemia), which often occur in patients with simultaneous oral hypoglycemic agents (such as glibenclamide/glibenclamide) or insulin using insulin. . Therefore, for such patients, it is recommended that their blood glucose changes be closely monitored. If the patient develops a hypoglycaemic response to the treatment with fleroxacin glucose, the drug should be discontinued immediately and appropriate treatment should be taken.
 
11, light sensitivity / phototoxicity
 
Moderate to severe photosensitivity/phototoxic reactions may occur after exposure to sunlight or ultraviolet light using fluoroquinolone antibiotics, which may exhibit excessive sunburn reactions (eg, burning sensation, erythema, blisters, exudation, Edema, often occurs in areas exposed to light (usually the "V" shaped area of ​​the neck, the forearm extensor surface, the back of the hand). Therefore, excessive exposure to light sources should be avoided. The drug should be discontinued when a phototoxic reaction occurs.
 
12, renal dysfunction should be used with caution, if used, should be adjusted according to the degree of declineDate of approval: November 14, 2006 Pilosin
 
Date of revision: December 02, 2011
 
          July 05, 2017
 
Fluroxacin glucose injection instructions
 
Please read the instructions carefully and use them under the guidance of a physician.
 
For food and feed processing
 
caveat:
 
Serious adverse reactions, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and increased myasthenia gravis.
 
· The use of fluoroquinolone drugs (including fleroxacin glucose injection) has been reported to have both severe and potentially irreversible serious adverse effects (see [Precautions]), including:
 
o Tendinitis and tendon rupture (see [Precautions])
 
o Peripheral neuropathy (see [Precautions])
 
o The effects of the central nervous system (see [Notes])
 
When these serious adverse reactions occur (see [Precautions]), fleroxacin glucose injection should be stopped immediately and fluoroquinolone drugs should be avoided.
 
· Fluoroquinolone drugs may aggravate the symptoms of myasthenia gravis in patients with myasthenia gravis. Patients with a history of myasthenia gravis should be advised to avoid fleroxacin glucose injection (see [Precautions]).
 
· Serious adverse reactions have been reported due to the use of fluoroquinolone drugs (including fleroxacin glucose injection) (see [Precautions]). For patients belonging to the following indications, fleroxacin should be used without other medications. Glucose Injection:
 
o Acute exacerbation of chronic bronchitis (see [Indications] and [Usage and Dosage])
 
 
 
【Drug Name】
 
    Generic name: fleroxacin glucose injection
 
    English name: Fleroxacin and Glucose Injection
 
    Pinyin: Fuluoshaxing Putaotang Zhusheye
 
[Ingredients] The main component of this product is: fleroxacin, its chemical name is: 6,8-difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1- Piperazinyl)-4-oxo-3-quinolinecarboxylic acid.
 
    Chemical Structure:
 
 
 
 
 
 
 
 
 
    Molecular formula: C17H18F3N3O3
 
Molecular weight: 369.34
 
Excipients are: glucose, lactic acid.
 
【Properties】 This product is a clear liquid with no color, light yellow or yellowish green.
 
[indications]
 
It can be used for acute bronchitis caused by sensitive bacteria, chronic bronchitis and pneumonia and other respiratory infections; cystitis, pyelonephritis, prostatitis, epididymitis, Neisseria gonorrhoeae urinary tract infections; Digestive system infections such as Salmonella typhimurium infection, bacterial dysentery; skin soft tissue infection, bone infection, abdominal infection and pelvic infection.
 
Serious adverse reactions have been reported due to the use of fluoroquinolones (including fleroxacin glucose injection), and for some patients, acute exacerbations of chronic bronchitis are self-limiting, and fleroxacin glucose should be used without other medications. Injection.
 
[Specification] 100ml: fleroxacin 0.4g and glucose 5.0g
 
[Usage and Dosage] Slow intravenous infusion, 0.2 ~ 0.4g (based on fleroxacin), once a day.
 
【Adverse reactions】
 
1. Serious and other important adverse reactions
 
Disabling and potentially irreversible serious adverse effects, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects
 
l tendonitis and tendon rupture
 
l myasthenia gravis aggravation
 
l QT interval extension
 
l allergic reactions
 
l other serious and potentially fatal reactions
 
l The influence of the central nervous system
 
l peripheral neuropathy
 
l Clostridium difficile-associated diarrhea
 
l Interference with blood sugar
 
l Light sensitivity / phototoxicity
 
The above adverse reactions are described in detail under [Precautions].
 
Cardiovascular system: prolonged QT interval, torsade de pointive ventricular tachycardia, ventricular arrhythmia
 
Central nervous system: convulsions, toxic psychosis, tremors, agitation, anxiety, dizziness, confusion, hallucinations, delusions, depression, nightmares, insomnia, seizures, and very few situations can lead to suicidal thoughts or actions
 
Peripheral neuropathy: feeling disorganized, feeling dull, feeling of touch, pain, burning, tingling, numbness, weakness, or light touch, pain, temperature, position and vibration abnormalities, polyneuritis
 
Skeletal muscle system: joint pain, myalgia, muscle weakness, tension hypertonic tendonitis, tendon rupture, worsening myasthenia gravis
 
Hypersensitivity reactions: urticaria, itching and other serious skin reactions (such as toxic epidermal necrolysis, erythema multiforme), dyspnea, angioedema (including tongue, throat, pharynx or facial edema/swelling), Cardiovascular collapse, hypotension, loss of consciousness, airway obstruction (including bronchospasm, shortness of breath and acute respiratory distress), hypersensitivity pneumonitis, anaphylactic shock
 
Hepatobiliary system: hepatitis, jaundice, acute hepatic necrosis or liver failure
 
Urinary system: acute renal insufficiency or renal failure
 
Blood system: anemia, including hemolytic anemia and aplastic anemia, thrombocytopenia, including thrombotic thrombocytopenic purpura, leukopenia, neutropenia, pancytopenia, and/or other blood diseases
 
Others: fever, vasculitis, serum disease, Clostridium difficile-associated diarrhea, blood glucose disorder, photosensitivity/phototoxicity
 
2, gastrointestinal reactions are more common, can be manifested as abdominal discomfort or pain, diarrhea, nausea and vomiting, loss of appetite, jaundice and so on.
 
3, the central nervous system reaction may have dizziness, headache, excitement, lethargy or insomnia, direction disorders and so on.
 
4, allergic reactions have rash, itchy skin, urticaria, palpitations, convulsions, occasional exudative erythema multiforme and vascular nerves
 
Sexual edema, severe cases can occur in shock. A small number of patients have photosensitivity reactions.
 
5, a small number of patients can occur blood aminotransferase, serum creatinine, blood urea nitrogen increased, peripheral blood like white blood cells decreased, thrombocytopenia,
 
Mostly mild and transient.
 
6, can happen:
 
(1) seizures, mental disorders, irritability, confusion, hallucinations, tremors.
 
(2) Interstitial nephritis manifestations such as hematuria, fever, and rash.
 
(3) Crystalline urine, more common in high-dose applications.
 
(4) joint pain.
 
(5) phlebitis.
 
(6) Interstitial pneumonia: fever, cough, difficulty breathing, chest X-ray abnormalities and other performance.
 
(7) Achilles tendon inflammation, Achilles tendon rupture, muscle pain, fatigue, increased CPK, etc.
 
[Contraindications] 1. Those who are allergic to this product or quinolones are prohibited.
 
2. Pregnant women, lactating women and patients under 18 years of age are banned.
 
【Precautions】
 
1. Disabling and potentially irreversible serious adverse reactions, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects
 
The use of fluoroquinolone drugs has been reported to cause disabling and potentially irreversible serious adverse reactions in different organ systems of the same patient, usually including: tendonitis, tendon rupture, joint pain, myalgia, peripheral neuropathy and Central nervous system reactions (illusions, anxiety, depression, insomnia, severe headaches and confusion). These adverse effects can occur from hours to weeks after the use of fleroxacin glucose injection. These adverse events have been reported in patients of any age without prior risk factors.
 
2, tendonitis and tendon rupture
 
Fluoroquinolone drugs increase the risk of tendonitis and tendon rupture in patients of all ages. This adverse reaction most often occurs in the Achilles tendon, which may require surgical repair. There have also been reports of tendonitis and tendon rupture in the shoulders, hands, biceps, thumb and other tendon points. Tendinitis and tendon rupture can occur hours or days after the start of the use of fleroxacin glucose injection, or several months after the end of treatment. Tendinitis and tendon rupture can occur bilaterally. This risk is further increased in elderly patients over 60 years of age, patients taking corticosteroids, and patients undergoing kidney, heart or lung transplants. In addition to age and the use of corticosteroids, factors that independently increase the risk of tendon rupture include severe physical activity, renal failure, and previous tendon diseases such as rheumatoid arthritis. Tendinitis and tendon rupture also occur in patients who use fluoroquinolone drugs without the above risk factors. Tendon rupture can occur during or after treatment; it is also reported that tendon rupture occurs several months after the end of treatment. This product should be discontinued after the patient has muscle pain, swelling, inflammation or breakage. After signs of tendonitis or tendon rupture, patients should be advised to rest and contact a physician for a non-quinolone. Patients with a history of tendon disease or who have had tendinitis and tendon rupture should avoid fluoroquinolone drugs.
 
3, myasthenia gravis aggravation
 
Fluoroquinolone drugs, which have neuromuscular blocking activity, may aggravate the symptoms of myasthenia gravis in patients with myasthenia gravis. Serious adverse events after marketing, including death and need for ventilatory support, and patients with myasthenia gravis are associated with the use of fluoroquinolones. Patients with myasthenia gravis should avoid the use of fleroxacin glucose injection.
 
4, QT interval extension
 
Some fluoroquinolone drugs can prolong the QT interval of the electrocardiogram, and a few patients can have arrhythmia. Patients with spontaneously reported fluoroquinolone therapy during the post-marketing surveillance period have a rare torsade ventricular tachycardia. Patients with known QT prolongation, uncorrected hypokalemia patients, and patients with antiarrhythmic drugs of class IA (quinidine, procainamide) and class III (amiodarone, sotalol) The use of fleroxacin glucose injection should be avoided. Elderly patients are more susceptible to drug-related QT intervals.
 
5, allergic reactions
 
Serious allergic reactions have been reported using fluoroquinolone drugs. Some patients occur after the first dose, and some reactions can be accompanied by cardiovascular failure, loss of consciousness, tingling, swallowing or facial edema, difficulty breathing, urticaria, itching, and the like. Severe allergic reactions require emergency treatment with adrenaline. Fleroxacin glucose injection should be discontinued the first time there is a rash or any other signs of allergies. If necessary, oxygen can be delivered, intravenous steroids, airway treatment, including intubation and other measures.
 
6. Other serious and potentially fatal reactions
 
Other serious and potentially fatal incidents have been reported using fluoroquinolone drugs. Some of these events are due to allergies and some are unknown. These events can be severe and usually occur after multiple doses. Clinical manifestations may include one or more of the following symptoms: fever, rash, severe skin reaction (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome); vasculitis; joint pain; myalgia; Allergic pneumonia; interstitial nephritis; acute renal insufficiency or renal failure; hepatitis, jaundice, acute hepatic necrosis or liver failure; anemia, including hemolytic anemia and aplastic anemia; thrombocytopenia, including thrombotic thrombocytopenia Purpura; leukopenia; agranulocytosis; pancytopenia and/or other hematological abnormalities. The drug should be discontinued and measures taken immediately on the first occurrence of a rash, jaundice or any other allergic manifestation.
 
7, the impact of the central nervous system
 
The use of fluoroquinolone drugs, including fleroxacin glucose injection, has been reported to increase the risk of increased central nervous system adverse events, including convulsions and increased intracranial pressure (including pseudo-brain tumors) and psychosis caused by poisoning. The use of fluoroquinolone drugs may cause central nervous system reactions including anxiety, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and suicidal thoughts or behaviors. These reactions may occur after the first dose. If these reactions occur when the patient is taking fleroxacin glucose injection, stop the administration and take appropriate measures. As with all fluoroquinolone drugs, patients with known or suspected central nervous system disorders (such as severe cerebral arteriosclerosis, epilepsy) or patients with other risk factors (if there is a tendency to attack or a lower threshold for seizures) should be obtained. Fluroxacin glucose injection is used when the risk exceeds the risk.
 
8, peripheral neuropathy
 
Patients have been reported to use fluoroquinolone drugs to produce a rare sensory or sensorimotor axonal neuropathy that affects small and/or large axons, causing skin paresthesia, sensation of dullness, sensation of touch and weakness. For some patients, symptoms may occur soon after administration of fleroxacin glucose injection and may be irreversible. If the patient has symptoms of peripheral neuropathy, including pain, burning sensation, tingling, numbness and/or weakness, or other sensations, including changes in light touch, pain, temperature, position, and vibration, stop the drug immediately. Patients with a history of peripheral neuropathy should avoid the use of fluoroquinolone antibiotics.
 
9. Clostridium difficile-associated diarrhea
 
Almost all antibacterial drugs have been reported for C. difficile-associated diarrhea (CDAD), including fleroxacin glucose injection, ranging from mild diarrhea to severe colitis. Antimicrobial treatment changes the normal flora of the colon, resulting in overgrowth of C. difficile.
 
Toxins A and B produced by C. difficile are responsible for Clostridium difficile-associated diarrhea. The morbidity and mortality caused by highly toxic Clostridium are elevated, and these infections are ineffective and may require colectomy. After receiving antibiotics, the possibility of CDAD should be considered in the presence of diarrhea. Because CDAD may occur two months after treatment with antibacterial drugs, careful medical history is necessary.
 
If you suspect or confirm C. difficile-associated diarrhea, you may need to stop the antibiotics currently used against C. difficile. Appropriate supplementation of fluids and electrolytes, protein supplementation, antibiotic treatment for C. difficile should be performed, and surgical evaluation should be performed when clinical indications appear.
 
10, interference with blood sugar
 
There have been reports of fluoroquinolone antibiotics causing blood glucose disorders (such as symptomatic hyperglycemia and hypoglycemia), which often occur in patients with simultaneous oral hypoglycemic agents (such as glibenclamide/glibenclamide) or insulin using insulin. . Therefore, for such patients, it is recommended that their blood glucose changes be closely monitored. If the patient develops a hypoglycaemic response to the treatment with fleroxacin glucose, the drug should be discontinued immediately and appropriate treatment should be taken.
 
11, light sensitivity / phototoxicity
 
Moderate to severe photosensitivity/phototoxic reactions may occur after exposure to sunlight or ultraviolet light using fluoroquinolone antibiotics, which may exhibit excessive sunburn reactions (eg, burning sensation, erythema, blisters, exudation, Edema, often occurs in areas exposed to light (usually the "V" shaped area of ​​the neck, the forearm extensor surface, the back of the hand). Therefore, excessive exposure to light sources should be avoided. The drug should be discontinued when a phototoxic reaction occurs.
 
12, renal dysfunction should be used with caution, if used, should be adjusted according to the degree of decline...
Online customer service
Customer service hotline
Service time:
-
Customer service group:
在线客服